FDG PET Scans May Predict Immunotherapy Outcomes in Melanoma and Solid Tumors
A Johns Hopkins pilot study tests whether FDG PET imaging can detect early tumor responses to immune checkpoint blockade before standard CT scans show changes.
Summary
Immune checkpoint blockade therapies work differently from chemotherapy — tumors may appear to grow before they shrink, confusing traditional CT-based response measurements. This pilot study from Johns Hopkins explored whether FDG PET/CT imaging, which measures tumor glucose metabolism rather than just size, could better capture early signs of treatment response. Researchers imaged 20 patients with melanoma, renal cell carcinoma, or non-small cell lung cancer before therapy, between days 21–28, and again at 4 months. Using PERCIST and immune RECIST criteria, they tracked metabolic changes in tumors to see if early shifts in glucose uptake predicted long-term progression-free and overall survival. The hope is that metabolic imaging can help clinicians distinguish true responses from pseudoprogression, enabling better-informed treatment decisions for patients on immunotherapy.
Detailed Summary
Immune checkpoint blockade has transformed cancer treatment, but its delayed and often unconventional response patterns create a real clinical challenge. Unlike chemotherapy, where tumor shrinkage can be tracked quickly, immunotherapy sometimes causes tumors to transiently enlarge before responding — a phenomenon that can mislead standard CT-based response criteria. Finding earlier, more reliable imaging biomarkers is critical for optimizing patient care.
This pilot study, conducted at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, enrolled 20 patients with advanced melanoma, renal cell carcinoma, or non-small cell lung cancer who were receiving immune checkpoint blockade therapy. The intervention was diagnostic rather than therapeutic: patients underwent FDG PET/CT scans at three time points — before treatment, between days 21 and 28, and at 4 months post-initiation.
Researchers applied PERCIST criteria to quantify peak and maximum standardized uptake values corrected for lean body mass, tumor volumes, and total glycolytic volumes. CT data from the same scans were analyzed using immune RECIST criteria to measure tumor size. The central question was whether metabolic changes visible on PET within the first month of therapy correlated with longer-term outcomes, including progression-free and overall survival.
The rationale draws on prior evidence: FDG PET has already proven highly predictive in radioimmunotherapy for lymphoma and has detected glycolytic changes as early as 7 days after immunotherapy initiation. Since melanomas consistently show high glucose metabolism, they are well-suited targets for this approach.
If validated, quantitative PET metrics could serve as early, objective biomarkers distinguishing responders from non-responders during immune checkpoint therapy — potentially sparing patients ineffective treatments and guiding timely switches to alternative regimens. This has direct relevance to aging populations, who bear a disproportionate burden of these cancers and may benefit most from avoiding unnecessary treatment toxicity. The study was completed in December 2018.
Key Findings
- FDG PET may detect tumor metabolic changes as early as 21–28 days into immune checkpoint therapy.
- Standard CT-based criteria can misinterpret immunotherapy responses; PET metabolic data may offer a more accurate alternative.
- PERCIST criteria quantify glycolytic tumor burden, potentially predicting progression-free and overall survival.
- Melanoma's consistently high glucose metabolism makes it an ideal candidate for FDG PET response monitoring.
- This 20-patient pilot aimed to link early PET changes to individual patient outcomes across three solid tumor types.
Methodology
This was a single-center, early-phase pilot study enrolling 20 patients with melanoma, RCC, or NSCLC receiving immune checkpoint blockade. FDG PET/CT was performed at baseline, days 21–28, and 4 months post-treatment, with quantitative analysis using PERCIST and immune RECIST criteria. The study was observational/diagnostic in design, not interventional.
Study Limitations
This summary is based on the abstract only, as the full study data are not publicly available. The 20-patient enrollment is very small, limiting statistical power and generalizability. Results from this pilot should be considered hypothesis-generating rather than definitive, pending validation in larger prospective trials.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: